FDA Reviewing Lynparza-bevacizumab as First-line Maintenance for Advanced Ovarian Cancer, Regardless of BRCA Status - January 14, 2020

[JLS1]

Since it appears there is some similarity in treatment for ovarian cancer and prostate cancer, I thought I'd share this, just out today via "Ovarian Cancer News Today":

FDA Reviewing Lynparza-bevacizumab as First-line Maintenance for Advanced Ovarian Cancer, Regardless of BRCA Status

JANUARY 14, 2020 Ana Pena, PhDBY ANA PENA, PHD IN NEWS.

ovariancancernewstoday.com/...

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

October 30, 2019 Marta Figueiredoby Marta Figueiredo

In News.

ovariancancernewstoday.com/...